Next Article in Journal
Sedating Mechanically Ventilated COVID-19 Patients with Volatile Anesthetics: Insights on the Last-Minute Potential Weapons
Previous Article in Journal
Triterpenic Acid Amides as a Promising Agent for Treatment of Metabolic Syndrome
Open AccessReview

Inhibitors of 11β-Hydroxysteroid Dehydrogenase Type 1 as Potential Drugs for Type 2 Diabetes Mellitus—A Systematic Review of Clinical and In Vivo Preclinical Studies

1
Faculty of Health Sciences, University of Beira Interior, 6200-506 Covilhã, Portugal
2
UFBI—Pharmacovigilance Unit of Beira Interior, University of Beira Interior, 6200-506 Covilhã, Portugal
3
CICS-UBI—Health Sciences Research Centre, University of Beira Interior, 6200-506 Covilhã, Portugal
*
Author to whom correspondence should be addressed.
Sci. Pharm. 2021, 89(1), 5; https://doi.org/10.3390/scipharm89010005
Received: 16 September 2020 / Revised: 8 December 2020 / Accepted: 25 December 2020 / Published: 5 January 2021
Diabetes mellitus is a pathology with increasing frequency in society, being one of the main causes of death worldwide. For this reason, new therapeutic targets have been studied over the years. 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) is an enzyme responsible for reducing cortisone to its active form cortisol, which can lead to metabolic changes such as insulin resistance and hyperglycemia. Therefore, 11β-HSD1 inhibition may offer a new therapeutic approach for type 2 diabetes mellitus. This work intends to systematically review the available scientific evidence on this subject. For this, a search was conducted in three databases and 15 clinical and in vivo preclinical studies were included in this review. Despite the high inhibitory and selectivity levels achieved with several molecules and the demonstrated clinical efficacy in diabetes treatment, no phase III clinical trials have yet been conducted. This is important because the long-term effects of 11β-HSD1 inhibitors including the consequences in hypothalamic–pituitary–adrenal axis must be evaluated. However, this enzyme remains a promising target for drug development, including due to its effectiveness in controlling various factors that constitute the metabolic syndrome and its potential for multiple indications in patients with diabetes, including wound healing and weight loss. View Full-Text
Keywords: type 2 diabetes mellitus; 11β-hydroxysteroid dehydrogenase type 1 inhibitors; cortisol; glycemic control type 2 diabetes mellitus; 11β-hydroxysteroid dehydrogenase type 1 inhibitors; cortisol; glycemic control
Show Figures

Graphical abstract

MDPI and ACS Style

Almeida, C.; Monteiro, C.; Silvestre, S. Inhibitors of 11β-Hydroxysteroid Dehydrogenase Type 1 as Potential Drugs for Type 2 Diabetes Mellitus—A Systematic Review of Clinical and In Vivo Preclinical Studies. Sci. Pharm. 2021, 89, 5.

AMA Style

Almeida C, Monteiro C, Silvestre S. Inhibitors of 11β-Hydroxysteroid Dehydrogenase Type 1 as Potential Drugs for Type 2 Diabetes Mellitus—A Systematic Review of Clinical and In Vivo Preclinical Studies. Scientia Pharmaceutica. 2021; 89(1):5.

Chicago/Turabian Style

Almeida, Cristiana; Monteiro, Cristina; Silvestre, Samuel. 2021. "Inhibitors of 11β-Hydroxysteroid Dehydrogenase Type 1 as Potential Drugs for Type 2 Diabetes Mellitus—A Systematic Review of Clinical and In Vivo Preclinical Studies" Sci. Pharm. 89, no. 1: 5.

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop